|
キタハラ シユウジ
Kitahara Shiyuuji
北原 秀治 所属 医学研究科 医学研究科 (医学部医学科をご参照ください) 職種 特任准教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. |
| 掲載誌名 | 正式名：Cancers 略 称：Cancers (Basel) ISSNコード：20726694/20726694 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 12(5),pp.E1275 |
| 著者・共著者 | Duda Dan G, Dima Simona O, Cucu Dana, Sorop Andrei, Klein Sebastian, Ancukiewicz Marek, Kitahara Shuji, Iacob Speranta, Bacalbasa Nicolae, Tomescu Dana, Herlea Vlad, Tanase Cristiana, Croitoru Adina, Popescu Irinel |
| 発行年月 | 2020/05 |
| 概要 | Background: Improving surgical outcomes in hepatocellular carcinoma (HCC) patients would greatly benefit from biomarkers. Angiogenesis and inflammation are hallmarks of HCC progression and therapeutic targets. Methods: We retrospectively evaluated preoperative clinical variables and circulating (plasma) biomarkers of angiogenesis and inflammation in a cohort of HCC patients who underwent liver resection (LR) or transplantation (LT). Biomarker correlation with outcomes-freedom of liver recurrence (FLR), disease-free survival (DFS) and overall survival (OS)-was tested using univariate and multivariate Cox regression analyses. Results: Survival outcomes associated with sVEGFR1, VEGF and VEGF-C in LT patients and with IL-10 in LR patients. Moreover, in LT patients within Milan criteria, higher plasma VEGF and sVEGFR1 were associated with worse outcomes, while in those outside Milan criteria lower plasma VEGF-C associated with better outcomes. Multivariate analysis indicated that adding plasma VEGF or VEGF-C to a predictive model including Milan criteria and AFP improved prediction of DFS and OS (all p < 0.05). Conclusion: Survival outcomes after LR or LT differentially associated with angiogenic and inflammatory biomarkers. High plasma VEGF correlated with poorer prognosis within Milan criteria while low plasma VEGF-C associated with better prognosis outside Milan criteria. These candidate biomarkers should be further validated to improve patient stratification. |
| DOI | 10.3390/cancers12051275 |
| PMID | 32443546 |